Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21186512 | 0.75 | BRD4 (0.34) | HDAC6 | |
| SCHEMBL5102670 | 0.72 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL22758636 | 0.68 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL7410855 | 0.67 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL29516712 | 0.66 | HDAC6 (0.31) | HDAC6 | |
| SCHEMBL21023590 | 0.66 | ESR1 (0.42) | ESR1ESR2 | |
| SCHEMBL20215138 | 0.65 | HDAC6 (0.38) | HDAC6 | |
| SCHEMBL18339611 | 0.64 | HDAC6 (0.37) | HDAC6 | |
| SCHEMBL24178335 | 0.64 | ESR1 (0.41) | ESR1ESR2 | |
| SCHEMBL18362081 | 0.64 | HDAC6 (0.35) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | ESR1 2830/4885ESR2 3452/4885HDAC6 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.